IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA

Summary

The purpose of the study is to better understand the factors present in the cells of inflamed joints of patients with arthritis that may cause rheumatoid arthritis. Knowledge gained from this study may lead to new and better therapies for arthritis.

Conditions

• Rheumatoid Arthritis

Interventions

OTHER

Lab Work

Lab work to measure IL-7 and IL-7R

DRUG

Certolizumab pegol (CDP870, tradename Cimzia)(prefilled syringes at the dose of 200mg)

Certolizumab pegol (CDP870, tradename Cimzia) or is provided in prefilled syringes at the dose of 200mg. Patients received 2x200mg at weeks 0, 2 and 4. Additionally a maintenance dose of 200mg is given every 2 weeks. Treatment is performed through subcutaneous injection.

DRUG

Certolizumab pegol (CDP870, tradename Cimzia)

rtolizumab pegol (CDP870, tradename Cimzia) or is provided in prefilled syringes at the dose of 200mg. Patients received 2x200mg at weeks 0, 2 and 4. Additionally a maintenance dose of 200mg is given every 2 weeks. Treatment is performed through subcutaneous injection.

DRUG

Hydroxychloroquine

some patients are on 400mg/day of hydroxychloroquine.

DRUG

Sulfasalazine

some patients are on 300 mg/day and some patients are on 1000 mg/day dose of sulfasalazine

DRUG

Medrol

some patients are on 8mg/day of medrol

DRUG

Prednisone

some patients are on 10mg /day, some patients are on 20 mg/day, some patients are on 2.5 mg/day, some patients are on 30 mg/day, and some patients are on 5 mg/day of prednisone

DRUG

Triamcinolone

some patients are on Triamcinolone 40-80mg IM monthly (received 40mg dose 1 week before blood draw, off enbrel 50mg weekly and SSZ 1000mg bid for \~ 3 months) some patients are on Triamcinolone 40mg IM monthly

DRUG

Naproxen

some patients are on 1000 mg/day of naproxen

DRUG

Leflunomide

some patients are on 20mg/day of leflunomide

DRUG

Methotrexate

some patients are on 20mg weekly, some patients are on 25mg weekly, some patients are on 17.5 mg, some patients are on 15 mg weekly, some patients are on 7.5 mg weekly, and some patients are on 15 mg weekly dose of methotrexate

DRUG

humira

some patients are on Humira 40mg q2weeks

Sponsors & Collaborators

• UCB Pharma

  collaborator INDUSTRY

• University of Illinois at Chicago

  lead OTHER

Principal Investigators

• Shiva Shahrara, PhD · UIC

Study Design

Allocation

NON_RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

NONE

Model

SEQUENTIAL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2015-08-31

Primary Completion

2017-09-30

Completion

2017-12-31

Countries

• United States

Study Locations